Defining acquisition cost when your buyer is a hospital committee

# Defining acquisition cost when your buyer is a hospital committee

A sales rep for a surgical robotics company spends 14 months courting a single 600-bed hospital. She trains surgeons on a demo unit, answers 40 procurement questions on sterilization workflow, and presents three times to the Value Analysis Committee (VAC), the internal panel that decides whether a device earns a spot on the hospital's approved purchasing list. Marketing ran two conference booths, a webinar series, and a peer-reviewed reprint campaign to support her.

Then the deal closes. What did that customer actually cost to acquire? If you answer with a consumer-marketing formula, you will be wrong by a wide margin.

Why standard CAC breaks in medtech

Customer Acquisition Cost (CAC) is the total sales and marketing spend needed to win one new customer, over a defined period, divided by the number of customers won.

$$CAC = \frac{\text{Sales spend} + \text{Marketing spend}}{\text{New customers acquired}}$$

In SaaS or e-commerce, the buyer is often one person and the cycle is days or weeks. In medtech and biotech, three things blow that model up:

Multiple buyers, one sale. You must persuade clinicians (who want it), procurement (who question the price), and the VAC (who weighs clinical evidence against budget). One "no" kills the deal.
Long cycles. Capital equipment sales commonly run 12 to 24 months. Spend and revenue land in different quarters.
Blended channels. Field reps, medical science liaisons (MSLs, scientists who discuss clinical data with physicians), congresses, and health economics content all touch the same deal.

So your CAC must span the full cycle and count every function that touched the account.

Building a fully loaded CAC

Start by defining the cohort window to match the sales cycle, not the fiscal quarter. If your average cycle is 18 months, measure spend across an 18-month window aligned to when those deals started.

Include these cost buckets:

1. Field sales: salaries, commissions, travel, demo unit depreciation, clinical specialists who support trials.

2. Marketing: congress booths, symposia, KOL (Key Opinion Leader, an influential physician) engagement, reprints, webinars, digital.

3. Health economics and outcomes research (HEOR) content built specifically to win VAC approval. This is a real marketing cost in medtech, not R&D.

4. Sales enablement: the collateral, ROI calculators, and clinical evidence dossiers reps carry into committees.

Exclude: manufacturing, ongoing service, and post-sale clinical training (that belongs to retention and cost to serve, not acquisition).

A worked example

Imagine a mid-size orthopedic implant company selling into US hospitals. Over an 18-month cohort:

| Cost bucket | Spend (18 mo) |

|---|---|

| Field sales (fully loaded) | $4,200,000 |

| Congresses and KOL programs | $900,000 |

| HEOR and VAC dossiers | $600,000 |

| Digital and enablement | $300,000 |

| Total | $6,000,000 |

New hospital accounts won in the cohort: 40.

$$CAC = \frac{6{,}000{,}000}{40} = \$150{,}000 \text{ per hospital account}$$

That number feels huge next to a $50 e-commerce CAC. It is only meaningful next to the account's lifetime value.

Pair CAC with LTV, always

Lifetime Value (LTV) is the total gross profit a customer generates over the relationship. A $150,000 CAC is excellent if that hospital buys implants worth millions over ten years, and alarming if they run one trial and churn.

The standard health check is the LTV:CAC ratio. A widely cited rule of thumb in B2B is that a ratio around 3:1 or higher is healthy, and below 1:1 means you lose money on every customer. Treat 3:1 as an industry heuristic, not a medtech-specific benchmark, since public medtech-specific figures are scarce and vary by segment.

Simple LTV for our implant account:

Annual gross profit per hospital: $120,000
Expected relationship: 8 years
Simple LTV = 120,000 x 8 = $960,000

$$\text{LTV:CAC} = \frac{960{,}000}{150{,}000} = 6.4\text{:}1$$

Strong. The long, expensive cycle is justified by a sticky, high-value account. For a full walk-through of the underlying math, the Corporate Finance Institute CAC primer is a solid free reference.

Segment CAC by buyer touchpoint

A blended CAC hides where money is wasted. Break spend down by the three committee stakeholders and ask which touch actually moves deals.

Clinician CAC: cost of KOL programs, congress education, and rep clinical support per won account.
Procurement CAC: cost of pricing tools, contract support, and GPO (Group Purchasing Organization, a body that negotiates prices for many hospitals at once) engagement.
VAC CAC: cost of HEOR dossiers and economic evidence.

In the US, GPOs like Vizient and Premier gatekeep a large share of hospital purchasing, so a deal can stall even after surgeons say yes. If you find that clinician enthusiasm is high but VAC approval stalls, your HEOR spend is underfunded relative to your KOL spend. That is a marketing allocation problem CAC segmentation reveals.

🎬 [VIDEO: "How Hospitals Actually Buy Medical Devices" — youtube.com — an overview of value analysis committees and the medtech purchasing chain]

US vs Europe: what changes

The buyer structure shifts across markets, and so does where your acquisition dollars go.

United States: private and system-level purchasing dominated by IDNs (Integrated Delivery Networks, large multi-hospital systems) and GPOs. Acquisition spend skews toward economic evidence and contracting.
Europe: many countries use centralized or national tender processes. In England, for example, NHS Supply Chain aggregates procurement. Winning often means qualifying for a tender rather than persuading a local committee, so acquisition spend skews toward regulatory dossiers, health technology assessment (HTA) evidence, and tender response capacity.

HTA bodies (such as NICE in England, the body that assesses whether a technology offers value for the health system) act as an evidence gate. In tender-driven markets, your CAC includes the cost of generating the exact economic evidence the assessment demands. Note these are structural descriptions; specific tender win rates and country CAC figures are not reliably published, so avoid quoting invented numbers to committees.

Attribution over an 18-month cycle

Long cycles make attribution hard. A congress touch in month 2 may enable a VAC win in month 16. Two practical approaches:

Multi-touch attribution: credit every touchpoint that appears in a won deal's history. Best when your CRM logs interactions well.
Cohort-based CAC: skip touch-level credit and simply divide total cohort spend by accounts won, as in the worked example. Cruder, but robust when data is messy.

Most medtech teams should start with cohort-based CAC because CRM hygiene across an 18-month, multi-stakeholder journey is usually poor. A minimal cohort query looks like this:

sql

SELECT
  cohort_start_quarter,
  SUM(sales_and_marketing_spend) AS total_spend,
  COUNT(DISTINCT won_account_id)  AS accounts_won,
  SUM(sales_and_marketing_spend) / COUNT(DISTINCT won_account_id) AS cac
FROM deal_cohorts
WHERE deal_start_date BETWEEN '2024-07-01' AND '2025-12-31'
GROUP BY cohort_start_quarter;

The key discipline: align the spend window to deal_start_date, not close date, so you are not comparing this quarter's spend against last year's wins.

Vérification des acquis

1. Why does the standard consumer-marketing CAC formula produce misleading results in medtech capital equipment sales?

2. Why does the lesson recommend defining the CAC cohort window to match the sales cycle rather than the fiscal quarter?

3. What is the primary implication of the fact that 'one no kills the deal' among clinicians, procurement, and the VAC?

CHOIX MULTIPLES

4. Select ALL correct answers about why a fully loaded CAC in medtech must count multiple functions.

Sélectionnez toutes les réponses correctes.

CHOIX MULTIPLES

5. Select ALL correct answers describing characteristics that distinguish medtech customer acquisition from typical SaaS or e-commerce acquisition.

Sélectionnez toutes les réponses correctes.

Payback period: the cash reality of long cycles

CAC payback period is how long it takes the customer's gross profit to repay their acquisition cost.

$$\text{Payback (months)} = \frac{CAC}{\text{Monthly gross profit per account}}$$

Modeling lifetime value across devices, disposables and service

Defining acquisition cost when your buyer is a hospital committee

Why standard CAC breaks in medtech

Building a fully loaded CAC

A worked example

Pair CAC with LTV, always

Segment CAC by buyer touchpoint

US vs Europe: what changes

Attribution over an 18-month cycle

Payback period: the cash reality of long cycles

Common ways teams get CAC wrong

Key Takeaways

Defining acquisition cost when your buyer is a hospital committee

Why standard CACCACCustomer Acquisition Cost (CAC) is the total sales and marketing spend divided by the number of new customers gained in a period. It measures how efficiently you grow.Voir la définition complète → breaks in medtech

Building a fully loaded CACCACCustomer Acquisition Cost (CAC) is the total sales and marketing spend divided by the number of new customers gained in a period. It measures how efficiently you grow.Voir la définition complète →

A worked example

Segment CACCACCustomer Acquisition Cost (CAC) is the total sales and marketing spend divided by the number of new customers gained in a period. It measures how efficiently you grow.Voir la définition complète → by buyer touchpoint

US vs Europe: what changes

AttributionAttributionA framework for assigning credit to the touchpoints that contributed to a conversion, so you can measure which channels and interactions actually drive results.Voir la définition complète → over an 18-month cycle

Payback period: the cash reality of long cycles

Common ways teams get CACCACCustomer Acquisition Cost (CAC) is the total sales and marketing spend divided by the number of new customers gained in a period. It measures how efficiently you grow.Voir la définition complète → wrong

Key Takeaways

Why standard CAC breaks in medtech

Building a fully loaded CAC

Segment CAC by buyer touchpoint

Attribution over an 18-month cycle

Common ways teams get CAC wrong